10:06 AM EDT, 03/31/2025 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said Monday that China's National Medical Products Administration approved its application to conduct a clinical trial evaluating pirfenidone capsules for radiation-induced lung injury, with or without immune-related pneumonitis.

The company said it expects to start the phase 2/3 trial to assess dosing and efficacy in H2 2025 at oncology and academic centers in China.

Shares of the company were down 1.8% in recent Monday trading.

Price: 8.95, Change: -0.16, Percent Change: -1.76